Jordan
Diabetes country report 2000 — 2050
Number of adults (20–79 years) with diabetes in Jordan (JO)
2000 | 194.2 thousand |
2011 | 291.6 thousand |
2024 | 1.1 million |
2050 | 2.2 million |
Jordan is one of the 21 countries and territories in the IDF Middle-East and North Africa Region.
Data source(s) used for the diabetes estimates in adults:
- Ajlouni K, Batieha A et al. Diabet Med 2019;36(9):1176-1182. doi: 10.1111/dme.1389. PMID:30614070.
- WHO STEPS Jordan 2019
Diabetes estimates (20-79 y) | ||||
---|---|---|---|---|
People with diabetes, in 1,000s | 194.2 | 291.6 | 1,086.5 | 2,172.4 |
Age-standardised prevalence of diabetes, % | - | 12.1 | 20.5 | 23.1 |
Proportion of people with undiagnosed diabetes, % | - | - | 18.6 | - |
People with undiagnosed diabetes, in 1,000s | - | - | 202.0 | - |
Impaired Fasting Glucose (IFG) | ||||
---|---|---|---|---|
People with IFG, in 1,000s | - | - | 157.3 | 254.8 |
Age-standardised prevalence of IFG, % | - | - | 2.5 | 2.5 |
Impaired Glucose Tolerance (IGT) | ||||
---|---|---|---|---|
People with IGT, in 1,000s | - | 220.7 | 549.6 | 989.0 |
Age-standardised prevalence of IGT, % | - | 8.3 | 9.4 | 10.2 |
Mortality attributable to diabetes (20-79 y) | ||||
---|---|---|---|---|
Deaths attributable to diabetes | - | 2,118.0 | 4,643.9 | - |
Proportion of diabetes-related deaths in people 20-79 y, % | - | - | 20.0 | - |
Hyperglycaemia in pregnancy (HIP) (20-49 y) | ||||
---|---|---|---|---|
Live births affected by HIP | - | - | 34,284.6 | - |
Prevalence of gestational diabetes mellitus (GDM), % | - | - | 12.7 | - |
Live births affected by other types of diabetes first detected in pregnancy | - | - | 1,200.1 | - |
Live births affected by other types of diabetes detected prior to pregnancy | - | - | 5,254.4 | - |
Diabetes-related health expenditure | ||||
---|---|---|---|---|
Total diabetes-related health expenditure, USD million | - | - | 927.6 | 1,486.2 |
Total diabetes-related health expenditure, ID million | - | - | 2,072.9 | 3,321.2 |
Diabetes-related health expenditure per person, USD | - | 544.0 | 853.7 | 684.1 |
Diabetes-related health expenditure per person, ID | - | - | 1,907.8 | 1,528.8 |
Type 1 diabetes estimates in children and adolescents | ||||
---|---|---|---|---|
People with type 1 diabetes (all age groups) | - | - | 25,881.0 | - |
People with type 1 diabetes (0-19 y) | - | - | 6,992.2 | - |
Demographics | ||||
---|---|---|---|---|
Total adult population (20-79 y), in 1,000s | 3,129.0 | 3,268.4 | 6,674.8 | 10,139.2 |
Population of children and adolescents (0-19 y) | - | - | 4,679,224.0 | - |
Diabetes estimates (20-79 y) | |
---|---|
People with diabetes, in 1,000s | 194.2 |
Age-standardised prevalence of diabetes, % | - |
Proportion of people with undiagnosed diabetes, % | - |
People with undiagnosed diabetes, in 1,000s | - |
Impaired Fasting Glucose (IFG) | |
---|---|
People with IFG, in 1,000s | - |
Age-standardised prevalence of IFG, % | - |
Impaired Glucose Tolerance (IGT) | |
---|---|
People with IGT, in 1,000s | - |
Age-standardised prevalence of IGT, % | - |
Mortality attributable to diabetes (20-79 y) | |
---|---|
Deaths attributable to diabetes | - |
Proportion of diabetes-related deaths in people 20-79 y, % | - |
Hyperglycaemia in pregnancy (HIP) (20-49 y) | |
---|---|
Live births affected by HIP | - |
Prevalence of gestational diabetes mellitus (GDM), % | - |
Live births affected by other types of diabetes first detected in pregnancy | - |
Live births affected by other types of diabetes detected prior to pregnancy | - |
Diabetes-related health expenditure | |
---|---|
Total diabetes-related health expenditure, USD million | - |
Total diabetes-related health expenditure, ID million | - |
Diabetes-related health expenditure per person, USD | - |
Diabetes-related health expenditure per person, ID | - |
Type 1 diabetes estimates in children and adolescents | |
---|---|
People with type 1 diabetes (all age groups) | - |
People with type 1 diabetes (0-19 y) | - |
Demographics | |
---|---|
Total adult population (20-79 y), in 1,000s | 3,129.0 |
Population of children and adolescents (0-19 y) | - |